1. Home
  2. SKIL vs BTAI Comparison

SKIL vs BTAI Comparison

Compare SKIL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$3.62

Market Cap

32.5M

Sector

Technology

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.51

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIL
BTAI
Founded
1998
2017
Country
United States
United States
Employees
2261
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.5M
35.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SKIL
BTAI
Price
$3.62
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.25
AVG Volume (30 Days)
123.9K
1.2M
Earning Date
04-13-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$1.17
52 Week High
$23.00
$8.08

Technical Indicators

Market Signals
Indicator
SKIL
BTAI
Relative Strength Index (RSI) 31.00 43.74
Support Level N/A $1.44
Resistance Level $4.84 $2.22
Average True Range (ATR) 0.43 0.14
MACD 0.09 0.00
Stochastic Oscillator 14.89 13.16

Price Performance

Historical Comparison
SKIL
BTAI

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: